Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

SBRT effective in primary tumor control, study finds

Many of the world's leading radiation oncologists are employing the unique capabilities of SBRT to treat a variety of cancers that often have defied conventional radiation therapy techniques. A multitude of studies evaluating SBRT are ongoing and investigators are publishing articles that demonstrate the effectiveness of this technique. Two studies led by renowned radiation oncologists were conducted at centers that use Elekta SBRT technology, and their results were published recently.

From Elekta 2 Apr 2010

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

IMS Health today reported 5.1 percent growth in 2009 U.S. sales of ethical pharmaceuticals and insulins through retail and non-retail channels, reaching $300.3 billion, compared with growth of 1.8 percent in 2008.

2 Apr 2010

Study reveals less invasive procedure beneficial for patients with sufficient lung function

Research published in the April edition of the Journal of Thoracic Oncology sought to compare the outcomes of a sleeve lobectomy and a pneumonectomy procedure, in order to determine which is a more acceptable standard treatment for patients with non-small cell lung cancer.

2 Apr 2010

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.

2 Apr 2010

APP, Fresenius Kabi and sanofi-aventis sign license and settlement agreements

Fresenius Kabi Pharmaceuticals Holding, Inc.,, the parent company of APP Pharmaceuticals, Inc., announced today that APP and other Fresenius Kabi companies have entered into license and settlement agreements with sanofi-aventis covering patents that apply to Eloxatin® (oxaliplatin injection and oxaliplatin for injection).

2 Apr 2010

New clues into genomic complexity of Mimivirus

A study published online today in the journal Genome Research offers surprising new clues into the genomic complexity of the giant Mimivirus, the largest known virus in the world. Previous studies have shown that unlike most viruses, the Mimivirus has more genes than many bacteria and performs functions that normally occur only in cellular organisms.

2 Apr 2010

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Radiology benefit management programs can protect patients from radiation exposure

Making sure patients receive the right diagnostic imaging tests at the right times in high-quality facilities significantly reduces unnecessary radiation exposure, HealthHelp chief medical officer Mark Hiatt, M.D., testified at a public meeting held by the U.S. Food and Drug Administration.

1 Apr 2010

Mount Sinai Medical Center's overall revenue growth for 2009 increased by 5%

Demonstrating the fortitude to address a challenging healthcare environment, president and C.E.O. Steven D. Sonenreich has led Mount Sinai Medical Center to financial stability and successfully reinforced its image as a healthcare leader. The most recent audit posted on March 26 reports nearly $14 million in profit for 2009.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

Role of membrane cholesterol in late keratinocyte differentiation analyzed

In a recent study initiated by Beiersdorf AG, Florian Spörl and colleagues evaluated the use of Roche Applied Science's xCELLigence System as a viable system to monitor not only cholesterol extraction and repletion but also cholesterol reorganization in human keratinocytes in real time. The xCELLigence System offers a novel approach to non-invasive long-term observation of membrane cholesterol dynamics in primary human keratinocytes.

1 Apr 2010

Dutasteride reduces risk of prostate cancer

There is good news for those at high risk for prostate cancer. The drug dutasteride which is manufactured by GlaxoSmithKline as the drug Avodart, has been found to reduce the risk of prostate cancer by a quarter. The drug is at present being used to treat enlarged prostates.

1 Apr 2010

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

31 Mar 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

DSMB for DIGNITY trial recommends Celsion continue enrollment

Celsion Corporation announced today that after reviewing safety data from the 40mg/m2 cohort, the DIGNITY Study Drug Safety Monitoring Board (DSMB) has recommended that Celsion continue to enroll patients in the trial and that new patients be treated at a ThermoDox® dose of 50mg/m2.

31 Mar 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

National Doctors' Day: St. Jude Children's Research Hospital honors physicians and staff

As physicians nationwide are acknowledged for their talent, sacrifice and courage on National Doctors' Day, St. Jude Children's Research Hospital honors its more than 230 staff and consulting physicians who strive to fulfill the hospital's mission each day.

31 Mar 2010

Investment report on Sunesis Pharmaceuticals

StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Oncology News and Research

Further Reading

SBRT effective in primary tumor control, study finds

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

Study reveals less invasive procedure beneficial for patients with sufficient lung function

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

APP, Fresenius Kabi and sanofi-aventis sign license and settlement agreements

New clues into genomic complexity of Mimivirus

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

Radiology benefit management programs can protect patients from radiation exposure

Mount Sinai Medical Center's overall revenue growth for 2009 increased by 5%

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Role of membrane cholesterol in late keratinocyte differentiation analyzed

Dutasteride reduces risk of prostate cancer

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

DSMB for DIGNITY trial recommends Celsion continue enrollment

Rosetta Genomics reports revenues of $150,000 for full-year 2009

National Doctors' Day: St. Jude Children's Research Hospital honors physicians and staff

Investment report on Sunesis Pharmaceuticals

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News